A retrospective, cohort study analyzing rate of disease reactivation after cessation of disease-modifying therapy in patients with Relapsing-Remitting Multiple Sclerosis
Latest Information Update: 24 Aug 2022
At a glance
- Drugs Fingolimod (Primary) ; Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
Most Recent Events
- 24 Aug 2022 New trial record
- 17 Aug 2022 Results published in the Neurology